Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Pfizer | Kioxia Holdings | EMCOR Group | |
|---|---|---|---|
| Moat rating | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. | narrow Kioxia's FY2025 Annual Securities Report (dated 2026-06-24) describes a real but bounded position. It records 'the limited number of major competitors in the flash memory business', and says its three manufacturing joint ventures with Sandisk let it 'make investments on a larger scale than if it were to invest alone and enjoy economies of scale in terms of capital expenditures and production efficiency'. Against that, the same Risk Factors section describes 'heavy global competition as advanced technologies are necessary for business execution', says 'in the flash memory market the Group's ability to decide prices is limited', that 'Some competitors possess technologies that the Group does not have, such as DRAM' and 'have greater financial strength than the Group', and records that the Group cut production from October 2022 to March 2024. Scale in a small field, not a barrier that protects Kioxia's returns through the cycle. | narrow The FY2025 Form 10-K describes an edge that holds on large, complex work but not across the trade. On the advantage side, it says an invitation to bid "is often conditioned upon prior experience, technical capability, and financial strength", that its largest projects "typically require significant technical and management skills and the financial strength to obtain performance bonds, which are often a condition to bidding for and winning these projects", and that those projects "represented approximately 58% of our electrical and mechanical construction services revenues in 2025". It adds: "We believe our financial position, operating results, access to bank credit and surety bonding, technical expertise including prefabrication, VDC, and BIM capabilities, and safety record, among other factors, give us an advantage over many of our competitors." Operating margin was 10.1% in 2025 against 9.2% in 2024, and the filing notes the 2025 figure includes a $144.9 million gain on the sale of the United Kingdom operations that "positively impacted operating margin by 85 basis points". On the limiting side, the same Competition section says "relatively few barriers exist to prevent entry into the electrical and mechanical construction services industry" and "there are relatively few barriers to entry into the building services industry". Item 1A adds that "Certain of our competitors have lower overhead cost structures and, therefore, are able to provide their services at lower rates than we are currently able to provide" and that work "is frequently awarded through a competitive bidding process". An advantage confined to bonded, technically demanding projects, in a trade the company itself calls easy to enter, is a narrow moat, not a wide one. |
| Moat type | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. | cost scale The advantage the company itself names is scale and capital efficiency. The Annual Securities Report says the Sandisk joint ventures, which procure the production equipment installed at Kioxia's Yokkaichi and Kitakami plants and 'sell 50% of their products to the Group and 50% to the Sandisk Group', let it 'enjoy economies of scale in terms of capital expenditures and production efficiency'. At its 2026 Investor Day (2026-06-02) management said that 'by leveraging our world-leading economies of scale, we have maintained a lower cost per gigabyte than the industry average', on a slide that cites the TechInsights NAND Market Report Q2 2026 as its source. The filing describes its technology work (layer stacking for BiCS FLASH, the move to QLC) and names 'a decline in competitiveness in production efficiency per gigabyte' as a risk if it falls behind. It does not present that technology as protected IP that rivals cannot match. | cost scale The 10-K places the advantage in capabilities that come with size rather than in customer lock-in or protected technology. The edge it names is "financial position, operating results, access to bank credit and surety bonding, technical expertise including prefabrication, VDC, and BIM capabilities, and safety record", delivered through "approximately 100 operating subsidiaries" and approximately 44,000 employees. MD&A credits the mechanical construction segment's 2025 result to "a more favorable mix of work and better project execution, including enhanced productivity, due in part to investments in virtual design and construction, prefabrication, and automation". Item 1A makes bonding a scale matter: "if we were to experience an interruption or reduction in the availability of bonding, we may be unable to compete for or work on certain projects." The filing cites no patents as a source of advantage, and switching costs are thin by its own account: "Many of our contracts, especially our building and industrial services contracts, may be canceled or delayed on short notice". |
| Leadership | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' | at parity TrendForce's 2Q26 NAND Flash ranking (2026-08-18) puts Kioxia fourth with revenue of about $10.72 billion. Its 13.6% share 'edged down', and it sits behind Samsung (29.3%), SK hynix Group and Micron, which moved up to third. TrendForce's 2Q26 enterprise SSD ranking (2026-09-01) also places it fourth, at $4.64 billion. On technology it is keeping pace: it began sampling the 332-layer 10th-generation BiCS FLASH on 2026-07-03, per its press release. The Annual Securities Report concedes that some competitors 'possess technologies that the Group does not have, such as DRAM' and 'have greater financial strength than the Group'. Kioxia is in the middle of a small group of peers. | co leader The 10-K gives no market share. It calls the field "highly fragmented" with "thousands of small companies across the United States", adds that "there are a number of larger companies focused on providing electrical and/or mechanical construction services, such as APi Group Corporation, Comfort Systems USA, Inc., Dycom Industries, Inc., Everus Construction Group, Inc., IES Holdings, Inc., MasTec, Inc., MYR Group Inc., Quanta Services, Inc., and Tutor Perini Corporation", and describes EMCOR as "one of the largest specialty contractors in the United States", which is the company's own account. Outside the filing: Wikipedia's EMCOR article (https://en.wikipedia.org/wiki/Emcor) states that "In 2025, the company was ranked 2nd by Engineering News-Record on its list of the largest 600 specialty contractors by revenue"; its footnote links ENR's 2025 Top 600 preview page, which refused this fetch with HTTP 403, so the rank was not read at ENR itself (the footnote's title also reads 2024 while its link is the 2025 page). Statista's summary of the ENR survey for 2018 (https://www.statista.com/statistics/467307/leading-us-firms-in-mechanical-based-on-revenue, published Oct 21, 2019) says "EMCOR Group was ranked as the leading mechanical contractor based in the United States in 2018" and that the overall survey was "topped by electrical contractor Quanta Services and closely followed by EMCOR Group". A filing-based check agrees on scale against one named rival: stored fundamentals from the FY2025 10-Ks show EMCOR revenue of $16,986,422 thousand against $9,101,641 thousand for Comfort Systems USA (https://www.sec.gov/Archives/edgar/data/1035983/000110465926017530/0001104659-26-017530-index.htm). Second place on a revenue ranking of 600 specialty contractors, in a field the 10-K says has thousands of firms, is co-leadership rather than clear leadership; the ranking evidence is second-hand or dated, so the band is held at co-leader and no higher. |
| Pricing power | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. | weak The Annual Securities Report states that 'in the flash memory market the Group's ability to decide prices is limited, and in the medium- to long-term selling prices on a bit basis may decline at a similar pace as in the past'. Current margins follow the market. The first-quarter FY2026 results attribute the revenue jump primarily to 'a significant increase in average selling prices (ASPs) resulting from strong demand from data center customers focusing on generative AI'. Gross profit was ¥1,380,066 million on revenue of ¥1,767,117 million, against ¥71,179 million on ¥342,799 million a year earlier. In the 2026 Investor Day Q&A management said it believes 'market pricing will continue to reflect those supply-demand conditions'. | moderate Margins have widened, but the filing says most work is bid. The 2025 Annual Report's five-year highlights show gross profit of $1,501,737 thousand on revenues of $9,903,580 thousand in 2021, $2,089,339 thousand on $12,582,873 thousand in 2023 and $3,282,988 thousand on $16,986,422 thousand in 2025; MD&A gives gross profit margin of 19.3% in 2025 against 19.0% in 2024. The Q2 2026 release (https://emcorgroup.com/application/files/3517/8535/6062/2Q26_Earnings_Release_Final.pdf) reports operating margin of 10.6% against 9.6% a year earlier, and the chief executive said "We remain focused on maintaining pricing discipline, carefully selecting project opportunities, and executing at a high level across our operations." The limits are in the 10-K: "Competition can place downward pressure on our contract prices and profit margins"; on commodities, "While we believe we can increase our prices to adjust for some price increases in commodities, there can be no assurance that price increases of commodities, if they were to occur, would be recoverable", and "certain of our contracts do not allow us to adjust our prices"; and Note 3 shows projects whose profitability was revised down by more than $1.0 million each reduced operating results by $85,941 thousand in 2025, against $66,319 thousand in 2024. |
| Summary | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. | Kioxia calls itself 'a specialized flash memory manufacturer'. It makes BiCS FLASH 3D NAND at Yokkaichi and Kitakami in Japan through three manufacturing joint ventures with Sandisk, whose output is sold 50% to Kioxia and 50% to Sandisk. FY2025 (year to March 2026) revenue was ¥2,337.6bn: SSD & Storage ¥1,362.6bn, Smart Devices ¥760.0bn and Other ¥215.0bn, with the Apple group alone at 20.4% of sales. Its moat is scale in a concentrated industry. TrendForce ranks it fourth in 2Q26 NAND revenue with a 13.6% share, and in August 2026 the partners announced anticipated investments in Japan of over $31 billion through 2032, contingent on government support. The same filing sets out the limits: limited ability to set prices; rivals that also make DRAM and have more financial strength; China's government-supported push for domestic semiconductor production; and a joint-venture agreement effective until 2034, with no decision yet on whether it continues after that. First-quarter FY2026 gross profit was ¥1,380,066 million on revenue of ¥1,767,117 million, against ¥71,179 million on ¥342,799 million a year earlier. The company attributes the jump primarily to a significant increase in average selling prices. | EMCOR Group installs and services electrical and mechanical systems in non-residential buildings and plants. Its FY2025 10-K reports revenues of $16.99 billion, approximately 72% from construction operations, approximately 21% from building services and approximately 7% from industrial services, through "approximately 100 operating subsidiaries"; the United Kingdom operations were sold on December 1, 2025. Data centres now drive the construction book: the network and communications market sector was $2,461,883 thousand, or 48%, of electrical construction segment revenue in 2025, against 34% in 2023, and $1,670,355 thousand, or 23%, of mechanical construction segment revenue, against 8% in 2023. Remaining performance obligations were $13.25 billion at the end of 2025, and the Q2 2026 results release (2026-07-30) put them at "a record $17.14 billion, compared to $11.91 billion as of June 30, 2025", with revenue guidance for 2026 raised to $20.00 billion - $20.50 billion. The 10-K's case for an edge is that bids for large work are "often conditioned upon prior experience, technical capability, and financial strength" and require performance bonds, and that EMCOR's balance sheet, bonding, prefabrication and VDC capabilities and safety record "give us an advantage over many of our competitors". The same filing sets the limits: the industry is "highly fragmented and our competition includes thousands of small companies across the United States", "relatively few barriers exist to prevent entry", most revenue comes from "projects requiring competitive bids", some rivals can price "at lower rates than we are currently able to provide", customers' in-house staff compete for building services, and the 10-K warns that if data centre spending "were to decrease, demand for our services could decline as we transition our resources to other sectors". Gross margin rose to 19.3% in 2025 from 19.0% in 2024, which MD&A attributes to "improved revenue mix and excellent project execution". A scale and execution edge on large, bonded projects, re-tested at every bid in an industry with low entry barriers, is a narrow moat. |
| Chain position | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. | Upstream NAND flash and SSD supplier. The filing says much of its revenue 'depends on a limited number of customers and industries, such as major smartphone manufacturers and large IT companies, including hyperscalers that require SSDs'. The Apple group was 20.4% of FY2025 sales. | EMCOR builds the electrical and mechanical plant inside facilities, increasingly data centres: the 10-K says capital spending on data center infrastructure "is rapidly expanding, which has increased demand for our services in recent years". It works directly for owners and "indirectly by acting as a subcontractor to general contractors, systems suppliers, construction managers, developers, property managers, and other subcontractors". Upstream, "we rely on third-party vendors and manufacturers to supply much of the materials and equipment necessary for our operations", with commodity exposure to "copper and steel" and fuel for a fleet of approximately 14,400 vehicles. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. |